康方生物-B(09926.HK):卡度尼利聯合IVONESCIMAB聯合或不聯合化療治療晚期非小細胞肺癌的Ib/II期臨牀研究獲批開展
格隆匯1月5日丨康方生物-B(09926.HK)發佈公吿,公司自主研發的全球首創新型腫瘤免疫治療新藥卡度尼利(PD-1/CTLA-4雙特異性抗體,研發代號:AK104)聯合公司自主研發的新型腫瘤免疫治療藥物Ivonescimab(PD-1/VEGF雙特異性抗體,研發代號:AK112),獲得中國國家藥品監督管理局藥品審評中心(CDE)批准,開展聯合或不聯合化療治療晚期非小細胞肺癌(“NSCLC”)的Ib/II期臨牀研究。
該臨牀研究是全球首個進入臨牀研究階段的“雙抗”加“雙抗”聯合療法。兩款基於PD-1的雙特異性抗體新藥的聯合應用,有望在現有以PD-1/PD-L1抑制劑為基石的免疫療法的基礎上,進一步提升免疫療法的臨牀效果。該臨牀研究也是公司充分挖掘自身豐富在研藥物臨牀價值和商業價值的又一重要體現。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.